Reports are confirming that arthritis experts are still suggesting the U. S. regulators to continue allowing testing of the new class of pain drug despite worries of the health authorities regarding the safety measures attached with the drugs.
In the year 2010, concerned authorities noticed an experimental remedy from the trial of the new class of pain drugs i. e. tanezumab, from Pfizer Inc. Scientists in Groton said that the drug can increase risk of joint damage, following which, they put a halt at the Pfizer’s drug trial.
But recently it has come up from some sources that federal Food and Drug Administration along with a panel is deciding to continue testing on the nerve-pain drugs, including Pfizer's experimental remedy as the drugs could primarily serve the patients, who are not affected or get relief from even stronger doses of Aleve or aspirin.
"There's significant risk but there are probably patient populations where there will be significant benefit," Lenore Buckley, a Professor at Virginia Commonwealth University School of Medicine and chair of the advisory panel, told Bloomberg news service.
Decision upon re-trials must be entirely of the FDA. Also, there are suggestions that the agency should weigh thoroughly some specific safety measures and drug-design parameters for the drugs that it decides to approve restarting the trials for.
Decision from the authority will pass re-trials not only for Pfizer’s drugs but there are also several other medicinal brands like Regeneron Pharmaceuticals, Johnson & Johnson and AstraZeneca, who’s trials or similar experimental programs are on hold for their respective new classes of drugs known as nerve growth factor inhibitors.
According to rough estimates, market for such drugs is approx worth $11 billion or even more.